Lagos PSN Tasks New Fellows on Local Manufacturing of Drugs

pharmanewsonline | May 06, 2019

Lagos PSN Tasks New Fellows on Local Manufacturing of Drugs
The main hall of the Sheraton Hotel was filled to capacity with men of timber and calibre in the Pharmaceutical Industry, as the Pharmaceutical Society of Nigeria (PSN) Lagos State branch, held its 2019 Annual Luncheon and Welcome Reception for Newly Inducted Fellows of PSN. The three-in-one event, also featured the N50 million fund raising exercise, for the completion of on-going secretariat building, as well as for the purchase of a 120KVA brand new generator, for the secretariat use.
Top among the list of dignitaries that graced the occasion were: The Governor-elect of Lagos State, Mr Babajide Sanwo-Olu; Dr Fidelis A. Ayebae, managing director, Fidson Healthcare Plc; Olumide Akintayo, former PSN president; Former chairmen of the state branch; Pharm. Oluwakemi Adeyeye, managing director, Boluke Pharmacy Ltd; Newly inducted Fellows of the state branch; Merit Award Winners of the branch, and others.

Spotlight

As the cloud becomes more prevalent, healthcare leaders are finding themselves in a multi-cloud environment, moving beyond basic infrastructure on demand to strategic innovations such as running real-time data analytics for the management of chronic disease patients.

Related News

Fixx Pharmaceuticals Wants to Dominate Hemophilia Market With Gene Editing

Prnewswire | August 28, 2020

Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. "We are looking to commercialize a product as soon as possible," says Jesse John Francis Clark, founder of Fixx. "We are going to develop a product that is more cost-effective for payers. We're looking to keep it under $2 million per patient," he said, saying that the overall cost of care of hemophilia patients will decrease. "If we are successful in developing a commercialized product, we are looking at upwards of $40 billion in sales from the U.S. market alone. I think our investors will be happy with that," says Clark.

Read More

U.S. states build stockpiles of malaria drug touted by Trump

Abcnews | April 26, 2020

State and local governments across the United States have obtained about 30 million doses of a malaria drug touted by President Trump to treat patients with the coronavirus, despite warnings from doctors that more research is needed. At least 22 states and Washington, D.C., secured shipments of the drug, hydroxychloroquine, according to information compiled from state and federal officials by The Associated Press. Sixteen of those states were won by Trump in 2016, although five of them, including North Carolina and Louisiana, are now led by Democratic governors. Supporters say having a supply on hand makes sense in case the drug is shown to be effective against the pandemic that has devastated the global economy and killed nearly 200,000 people worldwide, and to ensure a steady supply for people who need it for other conditions like lupus. But health experts worry that having the drug easily available at a time of heightened public fear could make it easier to misuse it. The U.S. Food and Drug Administration on Friday warned doctors against prescribing the drug, hydroxychloroquine, for treating the coronavirus outside of hospitals or research settings because of reports of serious side effects, including dangerous irregular heart rhythms and death among patients.

Read More

PCI Pharma Services Announces Global Clinical Footprint With Creation COE in Western Europe

PCI Pharma Services | July 28, 2020

PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin location, a major investment that will represent a new flagship site for customers. This is part of PCI’s global strategy to expand its clinical supply-chain network into continental Europe to complement offerings available at its UK and Ireland sites. The COE is expected to be completed in January 2021. “With this expansion, our Berlin Clinical Center of Excellence will address the needs of European and global clients,” said Brian Keesee, vice president and general manager, Global Clinical Operations and Supply, PCI Pharma Services. “Berlin is an excellent logistical hub that will serve as a proactive solution to Brexit, ensuring there are no gaps in the supply chain and our clients conducting clinical trials in all parts of Europe continue to be served.”

Read More

Spotlight

As the cloud becomes more prevalent, healthcare leaders are finding themselves in a multi-cloud environment, moving beyond basic infrastructure on demand to strategic innovations such as running real-time data analytics for the management of chronic disease patients.